Processa Pharmaceuticals, Inc. to acquire Vidya Therapeutics, Inc.

Processa Pharmaceuticals, Inc. has agreed to acquire Vidya Therapeutics, Inc. in a strategic acquisition within the healthcare sector. The transaction was announced and completed on 28 July 2026. Both the buyer and the target are based in the United States. The deal consideration consists of shares. The financial value of the transaction was not disclosed to the public. This structure indicates a full integration of the target’s operations into the acquirer’s existing business framework. The move expands Processa’s portfolio in the biopharmaceutical space through the acquisition of Vidya’s assets and intellectual property. The parties have finalised all necessary steps to close the deal on the same day it was announced. This rapid completion suggests that regulatory and shareholder approvals were secured efficiently prior to the public announcement. The acquisition represents a significant step for Processa Pharmaceuticals in consolidating its position within the competitive healthcare market.

The transaction is now complete. Vidya Therapeutics operates as a subsidiary of Processa Pharmaceuticals following the successful transfer of ownership. The share-based consideration implies that Vidya’s shareholders now hold equity in the combined entity. This arrangement aligns the interests of the former target owners with the long-term success of the acquirer. The deal marks the end of Vidya Therapeutics’ independent existence as a publicly traded or private entity. Processa Pharmaceuticals has assumed full control over Vidya’s research and development pipelines. The integration phase is expected to focus on combining technical teams and resources. No further regulatory hurdles remain for this specific transaction. The deal stands as a completed example of a share-based strategic acquisition in the US healthcare sector.